Esperion Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
324.76 |
350.51 |
328.29 |
442.36 |
552.70 |
1,050.70 |
| Przychód Δ r/r |
0.00% |
7.93% |
-6.34% |
34.75% |
24.94% |
90.10% |
| Przychód (min) |
314.34 |
174.23 |
257.50 |
442.36 |
365.18 |
694.21 |
| Przychód (max) |
333.07 |
412.65 |
413.18 |
442.36 |
668.03 |
1,269.94 |
| EBITDA (średnia) |
-227.73 |
-245.78 |
-230.20 |
-310.18 |
-387.56 |
-736.76 |
| EBIT (średnia) |
-227.90 |
-245.96 |
-230.37 |
-310.41 |
-387.85 |
-737.31 |
| EBIT % |
-70.17% |
-70.17% |
-70.17% |
-70.17% |
-70.17% |
-70.17% |
| Zysk netto (średni) |
-57.42 |
-30.89 |
-43.60 |
40.86 |
119.80 |
542.83 |
| Zysk netto % |
-17.68% |
-8.81% |
-13.28% |
9.24% |
21.67% |
51.66% |
| EPS (średnia) |
-0.32 |
-0.17 |
-0.20 |
0.21 |
0.64 |
2.90 |
| Liczba analityków (Przychody) |
7 |
6 |
8 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
6 |
5 |
6 |
5 |
2 |
1 |
| symbol |
ESPR |
ESPR |
ESPR |
ESPR |
ESPR |
ESPR |